drugset / Trial / NCT00088140
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.
Timeline
- Start
- 2004-07
- Primary completion
- 2005-10
- Completion
- 2005-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Emricasan | Small molecule | 5 mg | Oral |
| Comparator | Emricasan | Small molecule | 25 mg | Oral |
| Comparator | Emricasan | Small molecule | 50 mg | Oral |